Biohaven says BHV-1300 cuts Graves’ disease autoantibodies by over 80% in Phase 1b study

Biohaven

Biohaven

BHVN

0.00
  • Biohaven disclosed new Phase 1b patient data, presented at its R&D and Analyst Day, for BHV-1300 in Graves’ disease and BHV-1400 in IgA nephropathy.
  • BHV-1300 showed rapid, sustained lowering of disease-driving antibodies, with thyroid hormone normalization in treated Graves’ patients.
  • BHV-1400 produced fast, selective reductions in the pathogenic antibody linked to IgA nephropathy, with early signals of improved kidney measures.
  • Both programs showed a tolerable safety profile, with no serious events reported in the patient studies.
  • Pivotal Phase 3 trials for both assets are slated to start in the coming weeks by mid-2026, using a self-administered autoinjector.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605270730PR_NEWS_USPR_____NE68684) on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.